Predictive capacity of the diagnostic criteria of metabolic syndrome on the insulin-resistance and the coronary risk;Capacidad predictiva de los criterios diagnósticos del síndrome metabólico sobre la resistencia a la insulina y el riesgo coronario

Medicina Clinica

Volumn 129, Issue 16, 2007, Pages 601-606

  Martínez Candela, Juan ^a,b   Nadal, Josep Franch ^b,c   Ortiz, Josefa Romero ^a   Domínguez, Carmen Cánovas ^a   Martín, Arístides Gallardo ^a   Yepes, María Luisa López ^d  

^a Centro de Salud Mariano Yago   (Spain)

^b Red GEDAPS   (Spain)

^c EAP Raval Sud   (Spain)

^d Hospital Virgen del Castillo   (Spain)

Author keywords

Coronary risk; Definitions; Metabolic syndrome

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; DEMOGRAPHY; FEMALE; HUMAN; INSULIN RESISTANCE; INSULINEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; PREVALENCE;

EID: 37449027920     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13111806     Document Type: Article

References (33)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
2. De Fronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
3. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1195-200.
4. Ford ES, Giles WH. A Comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575-81.
5. Alberti KGMM, Zimmet PZ, and Working group members. World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
7. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, and European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364-76.
8. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62. Disponible en: http://www.idf.org/webdata/docs/ IDF_Metasyndrome_definition.pdf
9. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation. 2000;102:179-84.
10. Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al; D.E.S.I.R. Study Group. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003;29:526-32.
11. Ascaso J, Gabriel R, Franch J, Goday A, Fernández de Bobadilla J, Ortega R, et al. Grado de concordancia de los distintos criterios que definen el síndrome metabólico en el estudio DESIRE. Avances en Diabetología. 2004;20 Supl 1:23.
12. Álvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin (Barc). 2003;120:172-4.
13. Álvarez A, López V, Suárez S, Arias T, Prieto MA, Díaz L. Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS. Med Clin (Barc). 2005;124:368-70.
14. Real JT, Cármena R. Importancia del síndrome metabólico y de su definición dependiendo de los criterios utilizados. Med Clin (Barc). 2005;124:376-8.
15. Khan R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:228-304.
16. Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
17. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-age men. JAMA. 2002;288:2709-16.
18. Anderson KM, Wilson PWF, Kannel WB. An update coronary risk profile. A statement for health professionals. Circulation. 1991;3:356-62.
19. Martínez Candela J, Gallardo A, Franch J, Romero J, Cánovas C, Gómez R. Análisis de las alteraciones del metabolismo hidrocarbonado en la población adulta de Yecla (Murcia). Aten Primaria. 2004;34:345-52.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
21. Foz M, Barbany M, Remesar K, Carrillo M, Aranceta J, García-Luna PP, et al. Comisión de redacción del documento «Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica». Med Clin (Barc). 2000;115:587-97.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
23. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Cuantificación de la insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética. Med Clin (Barc). 2001;117:530-3.
24. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med. 2003;14:101-6.
25. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52:2160-7.
26. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, et al; for Finnish Diabetes Prevention Study Group. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004;27:2135-40.
27. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-9.
28. Adams RJ, Appleton S, Wilson DH, Tylor AW, Dal E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome. Diabetes Care. 2005;28:2777-9.
29. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin. 2005;21:1157-9.
30. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-9.
31. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K; Greenland Population Study. Prevalence of the metabolic syndrome among the Inuit in Greenland. A comparison between two proposed definitions. Diabetic Med. 2004;21:1237-42.
32. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112:666-73.
33. Navarro Pérez J, Navarro Adam A, García Sánchez L, Navarro Quesada JM. Manejo integral del síndrome metabólico. FMC. 2005;12:293-302.